A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)

Administered By

Awarded By

Contributors

Start/End

  • July 27, 2018 - July 15, 2023